Cargando…
Design of the HEM-POWR study: a prospective, observational study of real-world treatment with damoctocog alfa pegol in patients with haemophilia A
INTRODUCTION: Haemophilia A is a rare bleeding disorder caused by defects in coagulation factor VIII (FVIII). Damoctocog alfa pegol (BAY 94–9027, Jivi, Bayer, Germany) is a site-specifically PEGylated, extended-half-life, recombinant FVIII, approved for use in previously treated patients (PTPs) aged...
Autores principales: | Sanabria, Martin, Álvarez Román, María Teresa, Castaman, Giancarlo, Janbain, Maissaa, Matsushita, Tadashi, Meijer, Karina, Oldenburg, Johannes, Friedl, Sabine, Reding, M T |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413870/ https://www.ncbi.nlm.nih.gov/pubmed/34475142 http://dx.doi.org/10.1136/bmjopen-2020-044997 |
Ejemplares similares
-
Twelve-month prevalence of haemarthrosis and joint disease using the Haemophilia Joint Health score: evaluation of the UK National Haemophilia Database and Haemtrack patient reported data: an observational study
por: Wilkins, Richard A, et al.
Publicado: (2022) -
Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study
por: Oldenburg, Johannes, et al.
Publicado: (2019) -
Assessment of global coagulation function under treatment with emicizumab concomitantly with bypassing agents in haemophilia A with inhibitor (UNEBI Study): multicentre open-label non-randomised clinical trial
por: Ogiwara, Kenichi, et al.
Publicado: (2022) -
Damoctocog Alfa Pegol: A Review in Haemophilia A
por: Paik, Julia, et al.
Publicado: (2019) -
Health-related quality of life of patients with haemophilia: a cross-sectional survey in the Northeast of China
por: Niu, Jinyu, et al.
Publicado: (2022)